Click here to get full coverage on New Analyst Forecast: $ASND Given $256 Price Target - Quiver Quantitative

New Analyst Forecast: $ASND Given $256 Price Target  Quiver Quantitative

New Analyst Forecast: $ASND Given $256 Price Target - Quiver Quantitative

Click here to get full coverage on Stifel Raises Price Target for Ascendis Pharma (ASND) to $256 | - GuruFocus

Stifel Raises Price Target for Ascendis Pharma (ASND) to $256 |  GuruFocus

Stifel Raises Price Target for Ascendis Pharma (ASND) to $256 | - GuruFocus

Click here to get full coverage on Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After FDA Major Amendment Extends TransCon CNP Review Timeline - simplywall.st

Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After FDA Major Amendment Extends TransCon CNP Review Timeline  simplywall.st

Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After FDA Major Amendment Extends TransCon CNP Review Timeline - simplywall.st

Click here to get full coverage on Ascendis Pharma’s Unexpected 7.2% Surge: Growth or Bubble? - timothysykes.com

Ascendis Pharma’s Unexpected 7.2% Surge: Growth or Bubble?  timothysykes.com

Ascendis Pharma’s Unexpected 7.2% Surge: Growth or Bubble? - timothysykes.com

Click here to get full coverage on Where are the Opportunities in (ASND) (ASND:CA) - news.stocktradersdaily.com

Where are the Opportunities in (ASND) (ASND:CA)  news.stocktradersdaily.com

Where are the Opportunities in (ASND) (ASND:CA) - news.stocktradersdaily.com

Click here to get full coverage on Ascendis: Q3 Results Validate The TransCon Platform (NASDAQ:ASND) - Seeking Alpha

Ascendis: Q3 Results Validate The TransCon Platform (NASDAQ:ASND)  Seeking Alpha

Ascendis: Q3 Results Validate The TransCon Platform (NASDAQ:ASND) - Seeking Alpha

Click here to get full coverage on The Bull Case For Ascendis Pharma (ASND) Could Change Following New Long-Term Renal Data on TransCon PTH - Yahoo Finance

The Bull Case For Ascendis Pharma (ASND) Could Change Following New Long-Term Renal Data on TransCon PTH  Yahoo Finance

The Bull Case For Ascendis Pharma (ASND) Could Change Following New Long-Term Renal Data on TransCon PTH - Yahoo Finance

Click here to get full coverage on Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades' - Benzinga

Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades'  Benzinga

Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades' - Benzinga

Click here to get full coverage on Ascendis (Nasdaq: ASND) TransCon CNP achondroplasia results published in JAMA Pediatrics - Stock Titan

Ascendis (Nasdaq: ASND) TransCon CNP achondroplasia results published in JAMA Pediatrics  Stock Titan

Ascendis (Nasdaq: ASND) TransCon CNP achondroplasia results published in JAMA Pediatrics - Stock Titan

Click here to get full coverage on Did FDA’s TransCon CNP Review Delay Just Shift Ascendis Pharma’s (ASND) Investment Narrative? - simplywall.st

Did FDA’s TransCon CNP Review Delay Just Shift Ascendis Pharma’s (ASND) Investment Narrative?  simplywall.st

Did FDA’s TransCon CNP Review Delay Just Shift Ascendis Pharma’s (ASND) Investment Narrative? - simplywall.st

Click here to get full coverage on Avoiding Lag: Real-Time Signals in (ASND) Movement - news.stocktradersdaily.com

Avoiding Lag: Real-Time Signals in (ASND) Movement  news.stocktradersdaily.com

Avoiding Lag: Real-Time Signals in (ASND) Movement - news.stocktradersdaily.com

Click here to get full coverage on A Look at Ascendis Pharma (NasdaqGS:ASND) Valuation Following Q3 Growth and Pipeline Progress - Yahoo Finance

A Look at Ascendis Pharma (NasdaqGS:ASND) Valuation Following Q3 Growth and Pipeline Progress  Yahoo Finance

A Look at Ascendis Pharma (NasdaqGS:ASND) Valuation Following Q3 Growth and Pipeline Progress - Yahoo Finance

Click here to get full coverage on New Analyst Forecast: $ASND Given $220.0 Price Target - Quiver Quantitative

New Analyst Forecast: $ASND Given $220.0 Price Target  Quiver Quantitative

New Analyst Forecast: $ASND Given $220.0 Price Target - Quiver Quantitative

Click here to get full coverage on Ascendis Pharma A/S (ASND) Delivers Positive Trial Results for Hypoparathyroidism Treatment - Yahoo Finance

Ascendis Pharma A/S (ASND) Delivers Positive Trial Results for Hypoparathyroidism Treatment  Yahoo Finance

Ascendis Pharma A/S (ASND) Delivers Positive Trial Results for Hypoparathyroidism Treatment - Yahoo Finance

Click here to get full coverage on FDA Review Delay for TransCon CNP Might Change the Case for Investing in Ascendis Pharma (ASND) - simplywall.st

FDA Review Delay for TransCon CNP Might Change the Case for Investing in Ascendis Pharma (ASND)  simplywall.st

FDA Review Delay for TransCon CNP Might Change the Case for Investing in Ascendis Pharma (ASND) - simplywall.st

Click here to get full coverage on Ascendis Pharma (NasdaqGS:ASND): Evaluating Valuation After Sharply Higher Share Price This Quarter - Yahoo Finance

Ascendis Pharma (NasdaqGS:ASND): Evaluating Valuation After Sharply Higher Share Price This Quarter  Yahoo Finance

Ascendis Pharma (NasdaqGS:ASND): Evaluating Valuation After Sharply Higher Share Price This Quarter - Yahoo Finance

Click here to get full coverage on New Analyst Forecast: $ASND Given $254.0 Price Target - Quiver Quantitative

New Analyst Forecast: $ASND Given $254.0 Price Target  Quiver Quantitative

New Analyst Forecast: $ASND Given $254.0 Price Target - Quiver Quantitative

Click here to get full coverage on Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $250 - 富途牛牛

Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $250  富途牛牛

Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $250 - 富途牛牛

Click here to get full coverage on Ascendis Pharma (NASDAQ: ASND) posts 91% therapy independence, 84% normocalcemia - Stock Titan

Ascendis Pharma (NASDAQ: ASND) posts 91% therapy independence, 84% normocalcemia  Stock Titan

Ascendis Pharma (NASDAQ: ASND) posts 91% therapy independence, 84% normocalcemia - Stock Titan

Click here to get full coverage on Raymond James Initiates Coverage of Ascendis Pharma A (ASND) with Strong Buy Recommendation - Nasdaq

Raymond James Initiates Coverage of Ascendis Pharma A (ASND) with Strong Buy Recommendation  Nasdaq

Raymond James Initiates Coverage of Ascendis Pharma A (ASND) with Strong Buy Recommendation - Nasdaq

Click here to get full coverage on Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade - Nasdaq

Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade  Nasdaq

Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade - Nasdaq

Click here to get full coverage on Is There an Opportunity in Ascendis Pharma After Regulatory Approval Fuels 52% Rally in 2025? - simplywall.st

Is There an Opportunity in Ascendis Pharma After Regulatory Approval Fuels 52% Rally in 2025?  simplywall.st

Is There an Opportunity in Ascendis Pharma After Regulatory Approval Fuels 52% Rally in 2025? - simplywall.st

Click here to get full coverage on How Investors Are Reacting To Ascendis Pharma (ASND) Achieving First Positive Operating Income and Pooled Data Milestone - Sahm

How Investors Are Reacting To Ascendis Pharma (ASND) Achieving First Positive Operating Income and Pooled Data Milestone  Sahm

How Investors Are Reacting To Ascendis Pharma (ASND) Achieving First Positive Operating Income and Pooled Data Milestone - Sahm

Click here to get full coverage on Bank of America Securities Reiterates a Buy on Ascendis Pharma (ASND) - Yahoo Finance

Bank of America Securities Reiterates a Buy on Ascendis Pharma (ASND)  Yahoo Finance

Bank of America Securities Reiterates a Buy on Ascendis Pharma (ASND) - Yahoo Finance

Click here to get full coverage on Ascendis Pharma (ASND) Shares Impacted by FAERS Database Report - GuruFocus

Ascendis Pharma (ASND) Shares Impacted by FAERS Database Report  GuruFocus

Ascendis Pharma (ASND) Shares Impacted by FAERS Database Report - GuruFocus

Click here to get full coverage on Ascendis Pharma (NASDAQ: ASND) to Host Third Quarter Results Call Nov. 12 at 4:30 p.m. ET - Stock Titan

Ascendis Pharma (NASDAQ: ASND) to Host Third Quarter Results Call Nov. 12 at 4:30 p.m. ET  Stock Titan

Ascendis Pharma (NASDAQ: ASND) to Host Third Quarter Results Call Nov. 12 at 4:30 p.m. ET - Stock Titan

Click here to get full coverage on Ascendis Pharma (ASND): Wedbush Reiterates Outperform Rating | A - GuruFocus

Ascendis Pharma (ASND): Wedbush Reiterates Outperform Rating | A  GuruFocus

Ascendis Pharma (ASND): Wedbush Reiterates Outperform Rating | A - GuruFocus

Click here to get full coverage on Ascendis Pharma AS (ASND) Q3 2025 Earnings Call Highlights: Stro - GuruFocus

Ascendis Pharma AS (ASND) Q3 2025 Earnings Call Highlights: Stro  GuruFocus

Ascendis Pharma AS (ASND) Q3 2025 Earnings Call Highlights: Stro - GuruFocus

Click here to get full coverage on Ascendis Pharma Grants Employee Warrants to Strengthen Market Position - TipRanks

Ascendis Pharma Grants Employee Warrants to Strengthen Market Position  TipRanks

Ascendis Pharma Grants Employee Warrants to Strengthen Market Position - TipRanks

Click here to get full coverage on Ascendis: After Long Bull Run, New Commercial Challenges Suggest Rating Downgrade (ASND) - Seeking Alpha

Ascendis: After Long Bull Run, New Commercial Challenges Suggest Rating Downgrade (ASND)  Seeking Alpha

Ascendis: After Long Bull Run, New Commercial Challenges Suggest Rating Downgrade (ASND) - Seeking Alpha

Click here to get full coverage on New Forecasts: Here's What Analysts Think The Future Holds For Ascendis Pharma A/S (NASDAQ:ASND) - Yahoo Finance

New Forecasts: Here's What Analysts Think The Future Holds For Ascendis Pharma A/S (NASDAQ:ASND)  Yahoo Finance

New Forecasts: Here's What Analysts Think The Future Holds For Ascendis Pharma A/S (NASDAQ:ASND) - Yahoo Finance

Click here to get full coverage on Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026 - Sahm

Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026  Sahm

Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026 - Sahm

Click here to get full coverage on Ascendis Pharma’s Stunning Leap Forward - StocksToTrade

Ascendis Pharma’s Stunning Leap Forward  StocksToTrade

Ascendis Pharma’s Stunning Leap Forward - StocksToTrade

Click here to get full coverage on Ascendis Pharma Faces FDA Delay for TransCon CNP Approval - MSN

Ascendis Pharma Faces FDA Delay for TransCon CNP Approval  MSN

Ascendis Pharma Faces FDA Delay for TransCon CNP Approval - MSN

Click here to get full coverage on Morgan Stanley Remains Bullish on Ascendis Pharma (ASND) - Insider Monkey

Morgan Stanley Remains Bullish on Ascendis Pharma (ASND)  Insider Monkey

Morgan Stanley Remains Bullish on Ascendis Pharma (ASND) - Insider Monkey

Click here to get full coverage on Can UBS’s Backing of Yorvipath Signal a Durable Edge for Ascendis Pharma (ASND) in Rare Disease? - Yahoo Finance

Can UBS’s Backing of Yorvipath Signal a Durable Edge for Ascendis Pharma (ASND) in Rare Disease?  Yahoo Finance

Can UBS’s Backing of Yorvipath Signal a Durable Edge for Ascendis Pharma (ASND) in Rare Disease? - Yahoo Finance

Click here to get full coverage on Ascendis Pharma deals with report of Yorvipath patient death (ASND:NASDAQ) - Seeking Alpha

Ascendis Pharma deals with report of Yorvipath patient death (ASND:NASDAQ)  Seeking Alpha

Ascendis Pharma deals with report of Yorvipath patient death (ASND:NASDAQ) - Seeking Alpha

Click here to get full coverage on Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga

Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call  Benzinga

Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga

Click here to get full coverage on NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA - PR Newswire

NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA  PR Newswire

NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA - PR Newswire

Click here to get full coverage on There's Reason For Concern Over Ascendis Pharma A/S' (NASDAQ:ASND) Price - 富途牛牛

There's Reason For Concern Over Ascendis Pharma A/S' (NASDAQ:ASND) Price  富途牛牛

There's Reason For Concern Over Ascendis Pharma A/S' (NASDAQ:ASND) Price - 富途牛牛

Click here to get full coverage on Ascendis Pharma A/S Q3 2025 Earnings Call Transcript - MarketBeat

Ascendis Pharma A/S Q3 2025 Earnings Call Transcript  MarketBeat

Ascendis Pharma A/S Q3 2025 Earnings Call Transcript - MarketBeat

Click here to get full coverage on Wolfe Research initiates Ascendis Pharma stock with Outperform rating on pipeline potential - Investing.com

Wolfe Research initiates Ascendis Pharma stock with Outperform rating on pipeline potential  Investing.com

Wolfe Research initiates Ascendis Pharma stock with Outperform rating on pipeline potential - Investing.com

Click here to get full coverage on Ascendis Pharma Announces PDUFA Goal Date Extension to February 28, 2026 for TransCon CNP NDA - Quiver Quantitative

Ascendis Pharma Announces PDUFA Goal Date Extension to February 28, 2026 for TransCon CNP NDA  Quiver Quantitative

Ascendis Pharma Announces PDUFA Goal Date Extension to February 28, 2026 for TransCon CNP NDA - Quiver Quantitative

Click here to get full coverage on Is Ascendis Pharma A/S (ASND) the Best Growth Stock to Buy According to Billionaires? - Yahoo Finance

Is Ascendis Pharma A/S (ASND) the Best Growth Stock to Buy According to Billionaires?  Yahoo Finance

Is Ascendis Pharma A/S (ASND) the Best Growth Stock to Buy According to Billionaires? - Yahoo Finance

Click here to get full coverage on New Analyst Forecast: $ASND Given $250.0 Price Target - Nasdaq

New Analyst Forecast: $ASND Given $250.0 Price Target  Nasdaq

New Analyst Forecast: $ASND Given $250.0 Price Target - Nasdaq

Click here to get full coverage on Why ASND stock attracts global investors - Rate Hike & Risk Managed Investment Signals - moha.gov.vn

Why ASND stock attracts global investors - Rate Hike & Risk Managed Investment Signals  moha.gov.vn

Why ASND stock attracts global investors - Rate Hike & Risk Managed Investment Signals - moha.gov.vn

Click here to get full coverage on A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $220 to $297 - 富途牛牛

A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $220 to $297  富途牛牛

A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $220 to $297 - 富途牛牛

Click here to get full coverage on Ascendis Pharma (ASND) Is Up 6.9% After EMA Filing for TransCon CNP in Achondroplasia Treatment - Sahm

Ascendis Pharma (ASND) Is Up 6.9% After EMA Filing for TransCon CNP in Achondroplasia Treatment  Sahm

Ascendis Pharma (ASND) Is Up 6.9% After EMA Filing for TransCon CNP in Achondroplasia Treatment - Sahm

Click here to get full coverage on Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years - Benzinga

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years  Benzinga

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years - Benzinga

Click here to get full coverage on FDA Fast-Tracks Revolutionary Achondroplasia Drug: TransCon CNP Shows Multiple Benefits Beyond Growth - Stock Titan

FDA Fast-Tracks Revolutionary Achondroplasia Drug: TransCon CNP Shows Multiple Benefits Beyond Growth  Stock Titan

FDA Fast-Tracks Revolutionary Achondroplasia Drug: TransCon CNP Shows Multiple Benefits Beyond Growth - Stock Titan

Click here to get full coverage on (ASND) Investment Analysis (ASND:CA) - news.stocktradersdaily.com

(ASND) Investment Analysis (ASND:CA)  news.stocktradersdaily.com

(ASND) Investment Analysis (ASND:CA) - news.stocktradersdaily.com

Click here to get full coverage on Earnings Flash (ASND) Ascendis Pharma Posts Q3 Loss 1 Euro, vs. FactSet Est of 0.24 Euro Loss - marketscreener.com

Earnings Flash (ASND) Ascendis Pharma Posts Q3 Loss 1 Euro, vs. FactSet Est of 0.24 Euro Loss  marketscreener.com

Earnings Flash (ASND) Ascendis Pharma Posts Q3 Loss 1 Euro, vs. FactSet Est of 0.24 Euro Loss - marketscreener.com

Click here to get full coverage on MAA Submission to EMA: Ascendis Seeks EU Approval for TransCon CNP to Treat Achondroplasia - Stock Titan

MAA Submission to EMA: Ascendis Seeks EU Approval for TransCon CNP to Treat Achondroplasia  Stock Titan

MAA Submission to EMA: Ascendis Seeks EU Approval for TransCon CNP to Treat Achondroplasia - Stock Titan

Click here to get full coverage on Red Velvet's Wendy Signs with ASND Label, Joining K-pop Icons fromis_9 - Stardust Mag

Red Velvet's Wendy Signs with ASND Label, Joining K-pop Icons fromis_9  Stardust Mag

Red Velvet's Wendy Signs with ASND Label, Joining K-pop Icons fromis_9 - Stardust Mag

Click here to get full coverage on Jefferies Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $235 - 富途牛牛

Jefferies Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $235  富途牛牛

Jefferies Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $235 - 富途牛牛

Click here to get full coverage on Girl group fromis_9 to release holiday song - Korea JoongAng Daily

Girl group fromis_9 to release holiday song  Korea JoongAng Daily

Girl group fromis_9 to release holiday song - Korea JoongAng Daily

Click here to get full coverage on Ascendis Pharma A/S (NASDAQ:ASND) Q3 2025 Earnings Call Transcript - Insider Monkey

Ascendis Pharma A/S (NASDAQ:ASND) Q3 2025 Earnings Call Transcript  Insider Monkey

Ascendis Pharma A/S (NASDAQ:ASND) Q3 2025 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on (ASND) Investment Performance Report (ASND:CA) - news.stocktradersdaily.com

(ASND) Investment Performance Report (ASND:CA)  news.stocktradersdaily.com

(ASND) Investment Performance Report (ASND:CA) - news.stocktradersdaily.com

Click here to get full coverage on Earnings Flash (ASND) Ascendis Pharma Posts Q3 Revenue 213.6M Euros, vs. FactSet Est of 213.2M Euros - marketscreener.com

Earnings Flash (ASND) Ascendis Pharma Posts Q3 Revenue 213.6M Euros, vs. FactSet Est of 213.2M Euros  marketscreener.com

Earnings Flash (ASND) Ascendis Pharma Posts Q3 Revenue 213.6M Euros, vs. FactSet Est of 213.2M Euros - marketscreener.com

Click here to get full coverage on Ascendis Pharma Publishes Pivotal Week 52 Results of TransCon CNP for Children with Achondroplasia in JAMA Pediatrics - Quiver Quantitative

Ascendis Pharma Publishes Pivotal Week 52 Results of TransCon CNP for Children with Achondroplasia in JAMA Pediatrics  Quiver Quantitative

Ascendis Pharma Publishes Pivotal Week 52 Results of TransCon CNP for Children with Achondroplasia in JAMA Pediatrics - Quiver Quantitative

Click here to get full coverage on Leerink Partners Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $200 - 富途牛牛

Leerink Partners Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $200  富途牛牛

Leerink Partners Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $200 - 富途牛牛

Click here to get full coverage on (ASND) Stock Market Analysis (ASND:CA) - news.stocktradersdaily.com

(ASND) Stock Market Analysis (ASND:CA)  news.stocktradersdaily.com

(ASND) Stock Market Analysis (ASND:CA) - news.stocktradersdaily.com

Click here to get full coverage on Optimistic Investors Push Ascendis Pharma A/S (NASDAQ:ASND) Shares Up 26% But Growth Is Lacking - simplywall.st

Optimistic Investors Push Ascendis Pharma A/S (NASDAQ:ASND) Shares Up 26% But Growth Is Lacking  simplywall.st

Optimistic Investors Push Ascendis Pharma A/S (NASDAQ:ASND) Shares Up 26% But Growth Is Lacking - simplywall.st

Click here to get full coverage on 5 fromis_9 Members Join ASND Agency, Announce 2025 Group Activities - Forbes

5 fromis_9 Members Join ASND Agency, Announce 2025 Group Activities  Forbes

5 fromis_9 Members Join ASND Agency, Announce 2025 Group Activities - Forbes

Click here to get full coverage on FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA - PR Newswire

FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA  PR Newswire

FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA - PR Newswire

Click here to get full coverage on (ASND) Stock Trading Blueprint (ASND:CA) - news.stocktradersdaily.com

(ASND) Stock Trading Blueprint (ASND:CA)  news.stocktradersdaily.com

(ASND) Stock Trading Blueprint (ASND:CA) - news.stocktradersdaily.com

Click here to get full coverage on Ascendis Pharma shares tumble as Q3 earnings miss overshadows revenue beat - Investing.com

Ascendis Pharma shares tumble as Q3 earnings miss overshadows revenue beat  Investing.com

ASND

Price Chart

Key Statistics

Technicals

About ASND

Latest News

New Analyst Forecast: $ASND Given $256 Price Target - Quiver Quantitative

Stifel Raises Price Target for Ascendis Pharma (ASND) to $256 | - GuruFocus

Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After FDA Major Amendment Extends TransCon CNP Review Timeline - simplywall.st

Advanced Charts

Top Gainers

Top Losers